AAPL336.91+3.89 (+1.17%) ▲|ABBV256.91-2.45 (-0.94%) ▼|ABT104.49+1.43 (+1.39%) ▲|ACN154.06+7.07 (+4.81%) ▲|ADBE237.75+12.64 (+5.62%) ▲|AMAT516.89-19.36 (-3.61%) ▼|AMD494.95-27.00 (-5.17%) ▼|AMGN376.26+0.22 (+0.06%) ▲|AMT166.74+0.07 (+0.04%) ▲|AMZN231.39-0.72 (-0.31%) ▼|AVGO383.22+1.30 (+0.34%) ▲|AXP335.39+9.22 (+2.83%) ▲|BA211.50+1.98 (+0.95%) ▲|BAC62.13+0.08 (+0.13%) ▲|BKNG186.79+9.33 (+5.26%) ▲|BLK1,062.14+6.47 (+0.61%) ▲|BMY62.56+0.47 (+0.76%) ▲|BNY157.77-0.51 (-0.32%) ▼|BRK-B497.18+2.25 (+0.45%) ▲|C133.10+0.91 (+0.69%) ▲|CAT873.28-15.45 (-1.74%) ▼|CL91.98+1.23 (+1.36%) ▲|CMCSA22.80+0.51 (+2.27%) ▲|COF207.05+4.21 (+2.08%) ▲|COP115.58-4.68 (-3.89%) ▼|COST951.58+16.55 (+1.77%) ▲|CRM173.60+9.94 (+6.07%) ▲|CSCO114.57+0.40 (+0.35%) ▲|CVS107.07-0.67 (-0.62%) ▼|CVX190.00-4.79 (-2.46%) ▼|DE625.02-3.14 (-0.50%) ▼|DHR196.50+5.00 (+2.61%) ▲|DIS96.65+1.80 (+1.90%) ▲|DUK128.83-1.69 (-1.29%) ▼|EMR149.30+1.36 (+0.92%) ▲|FDX310.79-4.17 (-1.32%) ▼|GD389.14+2.39 (+0.62%) ▲|GE361.61+7.88 (+2.23%) ▲|GEV996.57-18.18 (-1.79%) ▼|GILD130.52+1.21 (+0.94%) ▲|GM87.04+4.40 (+5.32%) ▲|GOOG326.57+7.48 (+2.34%) ▲|GOOGL326.56+6.82 (+2.13%) ▲|GS1,048.23-13.00 (-1.23%) ▼|HD336.09+3.11 (+0.93%) ▲|HON245.75+2.60 (+1.07%) ▲|IBM216.28+2.09 (+0.98%) ▲|INTC91.67-0.65 (-0.70%) ▼|INTU303.91+7.58 (+2.56%) ▲|ISRG356.83+19.33 (+5.73%) ▲|JNJ265.95+2.55 (+0.97%) ▲|JPM356.20+2.99 (+0.85%) ▲|KO84.07+1.82 (+2.21%) ▲|LIN507.02-5.26 (-1.03%) ▼|LLY1,197.53+1.50 (+0.13%) ▲|LMT580.00-2.60 (-0.45%) ▼|LOW211.55+3.91 (+1.88%) ▲|LRCX291.61-13.60 (-4.46%) ▼|MA551.71+12.05 (+2.23%) ▲|MCD270.67+5.91 (+2.23%) ▲|MDLZ60.67+0.15 (+0.25%) ▲|MDT84.22+1.01 (+1.21%) ▲|META593.87-1.32 (-0.22%) ▼|MMM178.23+5.61 (+3.25%) ▲|MO72.89-0.10 (-0.14%) ▼|MRK130.76-0.31 (-0.24%) ▼|MS214.56+0.08 (+0.04%) ▲|MSFT389.10+7.40 (+1.94%) ▲|MU900.20-20.75 (-2.25%) ▼|NEE88.83-0.95 (-1.06%) ▼|NFLX70.40+0.31 (+0.44%) ▲|NKE42.14+0.44 (+1.06%) ▲|NOW105.56+6.78 (+6.86%) ▲|NVDA196.51-10.33 (-4.99%) ▼|ORCL119.90+4.91 (+4.27%) ▲|PEP139.79+3.15 (+2.31%) ▲|PFE24.67+0.13 (+0.53%) ▲|PG148.63+1.22 (+0.83%) ▲|PLTR131.53+8.61 (+7.00%) ▲|PM195.66+2.66 (+1.38%) ▲|QCOM170.04+3.07 (+1.84%) ▲|RTX218.42+5.63 (+2.65%) ▲|SBUX103.65+0.40 (+0.39%) ▲|SCHW104.18+2.21 (+2.17%) ▲|SO96.48-0.77 (-0.79%) ▼|SPG231.67+1.89 (+0.82%) ▲|T24.42+0.29 (+1.20%) ▲|TMO559.53-8.73 (-1.54%) ▼|TMUS177.21-2.88 (-1.60%) ▼|TSLA309.22-3.81 (-1.22%) ▼|TXN279.41-0.17 (-0.06%) ▼|UBER68.18+2.24 (+3.40%) ▲|UNH417.64-3.10 (-0.74%) ▼|UNP299.30-8.02 (-2.61%) ▼|UPS112.95-1.84 (-1.60%) ▼|USB63.49-0.48 (-0.75%) ▼|V362.53+6.79 (+1.91%) ▲|VZ47.32+0.94 (+2.03%) ▲|WFC87.27+0.96 (+1.11%) ▲|WMT111.74+2.27 (+2.07%) ▲|XOM154.77-2.17 (-1.38%) ▼|AAPL336.91+3.89 (+1.17%) ▲|ABBV256.91-2.45 (-0.94%) ▼|ABT104.49+1.43 (+1.39%) ▲|ACN154.06+7.07 (+4.81%) ▲|ADBE237.75+12.64 (+5.62%) ▲|AMAT516.89-19.36 (-3.61%) ▼|AMD494.95-27.00 (-5.17%) ▼|AMGN376.26+0.22 (+0.06%) ▲|AMT166.74+0.07 (+0.04%) ▲|AMZN231.39-0.72 (-0.31%) ▼|AVGO383.22+1.30 (+0.34%) ▲|AXP335.39+9.22 (+2.83%) ▲|BA211.50+1.98 (+0.95%) ▲|BAC62.13+0.08 (+0.13%) ▲|BKNG186.79+9.33 (+5.26%) ▲|BLK1,062.14+6.47 (+0.61%) ▲|BMY62.56+0.47 (+0.76%) ▲|BNY157.77-0.51 (-0.32%) ▼|BRK-B497.18+2.25 (+0.45%) ▲|C133.10+0.91 (+0.69%) ▲|CAT873.28-15.45 (-1.74%) ▼|CL91.98+1.23 (+1.36%) ▲|CMCSA22.80+0.51 (+2.27%) ▲|COF207.05+4.21 (+2.08%) ▲|COP115.58-4.68 (-3.89%) ▼|COST951.58+16.55 (+1.77%) ▲|CRM173.60+9.94 (+6.07%) ▲|CSCO114.57+0.40 (+0.35%) ▲|CVS107.07-0.67 (-0.62%) ▼|CVX190.00-4.79 (-2.46%) ▼|DE625.02-3.14 (-0.50%) ▼|DHR196.50+5.00 (+2.61%) ▲|DIS96.65+1.80 (+1.90%) ▲|DUK128.83-1.69 (-1.29%) ▼|EMR149.30+1.36 (+0.92%) ▲|FDX310.79-4.17 (-1.32%) ▼|GD389.14+2.39 (+0.62%) ▲|GE361.61+7.88 (+2.23%) ▲|GEV996.57-18.18 (-1.79%) ▼|GILD130.52+1.21 (+0.94%) ▲|GM87.04+4.40 (+5.32%) ▲|GOOG326.57+7.48 (+2.34%) ▲|GOOGL326.56+6.82 (+2.13%) ▲|GS1,048.23-13.00 (-1.23%) ▼|HD336.09+3.11 (+0.93%) ▲|HON245.75+2.60 (+1.07%) ▲|IBM216.28+2.09 (+0.98%) ▲|INTC91.67-0.65 (-0.70%) ▼|INTU303.91+7.58 (+2.56%) ▲|ISRG356.83+19.33 (+5.73%) ▲|JNJ265.95+2.55 (+0.97%) ▲|JPM356.20+2.99 (+0.85%) ▲|KO84.07+1.82 (+2.21%) ▲|LIN507.02-5.26 (-1.03%) ▼|LLY1,197.53+1.50 (+0.13%) ▲|LMT580.00-2.60 (-0.45%) ▼|LOW211.55+3.91 (+1.88%) ▲|LRCX291.61-13.60 (-4.46%) ▼|MA551.71+12.05 (+2.23%) ▲|MCD270.67+5.91 (+2.23%) ▲|MDLZ60.67+0.15 (+0.25%) ▲|MDT84.22+1.01 (+1.21%) ▲|META593.87-1.32 (-0.22%) ▼|MMM178.23+5.61 (+3.25%) ▲|MO72.89-0.10 (-0.14%) ▼|MRK130.76-0.31 (-0.24%) ▼|MS214.56+0.08 (+0.04%) ▲|MSFT389.10+7.40 (+1.94%) ▲|MU900.20-20.75 (-2.25%) ▼|NEE88.83-0.95 (-1.06%) ▼|NFLX70.40+0.31 (+0.44%) ▲|NKE42.14+0.44 (+1.06%) ▲|NOW105.56+6.78 (+6.86%) ▲|NVDA196.51-10.33 (-4.99%) ▼|ORCL119.90+4.91 (+4.27%) ▲|PEP139.79+3.15 (+2.31%) ▲|PFE24.67+0.13 (+0.53%) ▲|PG148.63+1.22 (+0.83%) ▲|PLTR131.53+8.61 (+7.00%) ▲|PM195.66+2.66 (+1.38%) ▲|QCOM170.04+3.07 (+1.84%) ▲|RTX218.42+5.63 (+2.65%) ▲|SBUX103.65+0.40 (+0.39%) ▲|SCHW104.18+2.21 (+2.17%) ▲|SO96.48-0.77 (-0.79%) ▼|SPG231.67+1.89 (+0.82%) ▲|T24.42+0.29 (+1.20%) ▲|TMO559.53-8.73 (-1.54%) ▼|TMUS177.21-2.88 (-1.60%) ▼|TSLA309.22-3.81 (-1.22%) ▼|TXN279.41-0.17 (-0.06%) ▼|UBER68.18+2.24 (+3.40%) ▲|UNH417.64-3.10 (-0.74%) ▼|UNP299.30-8.02 (-2.61%) ▼|UPS112.95-1.84 (-1.60%) ▼|USB63.49-0.48 (-0.75%) ▼|V362.53+6.79 (+1.91%) ▲|VZ47.32+0.94 (+2.03%) ▲|WFC87.27+0.96 (+1.11%) ▲|WMT111.74+2.27 (+2.07%) ▲|XOM154.77-2.17 (-1.38%) ▼|
24 C
New York
Tuesday, July 28, 2026

Tag: US8776191061

newssourceFORcompanyinformationcontent1releasesmarket

Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

DALLAS, June 24, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced the pricing of an underwritten public offering of 32,500,001 shares of its common stock at a price to the public of $6.00 per share and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase 833,333 shares of its common stock at an offering price of $5.999 per pre-funded warrant, in each case before underwriting discounts and commissions. All of the securities are being offered by Taysha. In addition, Taysha has granted the underwriters a 30-day option to purchase up to an additional 5,000,000 shares of common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds from the offering to Taysha are expected to be approximately $200.0 million, before deducting underwriting discounts and commissions and other offering expenses, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on or about June 26, 2026, subject to customary closing conditions.

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

DALLAS, June 05, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on June 1, 2026, the Compensation Committee of Taysha's Board of Directors granted four new employees, in the aggregate, restricted stock units (RSUs) representing 714,700 shares of the Company’s common stock and an option to purchase 468,600 shares of the Company's common stock in connection with their employment. The RSUs and stock option were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

DALLAS, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on August 1, 2025, the Compensation Committee of Taysha's Board of Directors granted one new employee an option to purchase 90,000 shares of the Company's common stock in connection with their employment. The stock option was granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individual entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

DALLAS, July 03, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on July 1, 2025, the Compensation Committee of Taysha's Board of Directors granted two new employees, in the aggregate, options to purchase 30,000 shares of the Company's common stock in connection with their employment. The stock options were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsUS8776191061

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers